KRAS and neoplasm: KRAS has been considered a viable tumor vaccine target, since mutant KRAS is exclusively present in cancer cells except for rare, dispersed cells within healthy colon tissue, although the direct effect of mutant KRAS in the oncogenesis of human and murine pancreatic cancer was recently addressed using CRISPR/Cas9-genome editing (10).